甲状腺眼病靶向药入医保 东莞爱尔首张处方自付降80%+

Core Viewpoint - The inclusion of the targeted drug Teprotumumab in the national medical insurance directory starting January 1, 2026, marks a significant advancement in the treatment of Thyroid Eye Disease (TED), providing financial relief for patients who previously faced high treatment costs [1][3]. Group 1: Drug and Treatment Details - Teprotumumab is the first domestically approved targeted therapy for TED, significantly reducing treatment costs from approximately 3 million yuan per course to under 6000 yuan per injection after insurance reimbursement [3][5]. - Patients like Ms. Li, who previously struggled with traditional treatments, can now access this innovative therapy, with personal costs reduced to 1909.12 yuan per injection after insurance [1][3]. Group 2: Clinical Impact and Patient Management - Early diagnosis and treatment are crucial for managing TED symptoms, which include eye bulging and vision impairment, potentially leading to severe complications [4]. - The Dongguan Aier Eye Hospital has established a specialized clinic for TED, offering comprehensive management from prevention to rehabilitation, ensuring tailored treatment plans for patients [5]. Group 3: Economic and Accessibility Implications - The inclusion of Teprotumumab in the insurance scheme signifies a new era of accessibility for TED treatment, allowing more patients to benefit from effective and safe targeted therapies [5]. - The policy change is expected to alleviate the financial burden on patients, enabling timely access to necessary treatments [5].